Bedrolite supply collapse raises alarm for severe epilepsy patients
A bankruptcy in the Dutch company behind Bedrolite has thrown the treatment plans of children and adults with severe, drug-resistant epilepsy into uncertainty. For families who say the cannabis-based medicine has kept catastrophic seizures under control for years, the loss of a reliable supply is not an administrative problem. It is a direct threat to seizure stability, school attendance, family life and, in some cases, survival.
Alfie, now 15, has been seizure-free for eight years after starting the medicine. Before that, he was having about 150 seizures a week. His family’s description of life before Bedrolite is stark: repeated hospital admissions, frequent multi-day stays, and a child whose condition existed in a constant state of crisis. For a patient with severe epilepsy, even a short interruption in an effective regimen can be enough to bring seizures roaring back.
That risk is especially unsettling because this is not a medication with a simple interchangeable substitute. Bedrolite is a specific cannabis formulation, and families say another cannabis oil would not necessarily reproduce the same effect. In neurology, that concern is credible. Seizure control often depends on a narrow balance of dose, formulation, and response over time. When a patient has already demonstrated a stable clinical response to one preparation, the prospect of switching carries real uncertainty, particularly after prior treatment failures.
Families fear a return to uncontrolled seizures
Maggie Deacon, Alfie’s grandmother, has taken on his case after the death of his mother, Hannah Deacon, who had previously campaigned to secure NHS prescribing for him. She described the earlier years as relentless and said her grandson could be pushed back into a cycle of hospital care and steroid bursts if the medicine disappears. Her warning reflects the harsh biology of refractory epilepsy: once seizure control is lost, regaining it is not always immediate, and in some patients the prior response does not return in the same way after treatment is stopped and restarted.
One sentence captures the clinical fear more accurately than any policy statement could.
If Bedrolite stops, some patients may deteriorate quickly enough to need urgent hospital care.
Emma Matthews described that possibility even more bluntly in relation to her son Louis Petit, now 23 and seizure-free for six years on the medicine. He began having seizures in 2016 at age 12 and later came off the oil in the past; his seizures returned immediately. Matthews said her son lives with the fear that severe seizures could kill him overnight if treatment is withdrawn. That is the reality of some epilepsy syndromes: the margin between stability and danger can be thin, and loss of seizure control may carry sudden consequences, including injury, aspiration, status epilepticus or death.
A medicine tied to one supply chain
Bedrocan, the Dutch company linked to the product, was declared bankrupt in October. Families have been told that supplies could run out within months. At present, there is still inventory in the Netherlands, but export has reportedly been restricted by the Dutch government to protect domestic supply. UK families are therefore facing a limited stock situation with no obvious immediate replacement.
The company said there is still Bedrolite inventory available in the Netherlands and that efforts are under way to restart the business. It also acknowledged contact with several UK families and the concern around treatment continuity. Those statements matter because they confirm what neurology teams already know from many chronic epilepsies: medication access is inseparable from disease control. A therapy can be effective on paper, but if the supply chain fails, the benefit vanishes.
There is also a practical problem around import dependence. The UK is believed to have about six months’ supply, but the long-term picture is unclear. Families are describing a medicine that is not manufactured domestically and may not be readily replaceable through the ordinary market. In a condition where missed doses can trigger breakthrough seizures, that dependency creates a fragile system.
Parliament and clinicians press for a back-up plan
Tonia Antoniazzi, the Labour MP for Gower, has led a campaign on medicinal cannabis in Parliament and has written to the health minister asking for action. Her argument is straightforward: if families already depend on a product that is difficult to replace, government should not wait for stock to disappear before intervening. She has called for a UK manufacturing solution, including the possibility of creating a similar product domestically.
That proposal reflects an uncomfortable truth about the current arrangement. When a treatment is imported and manufactured abroad, every weak point in the chain becomes a clinical risk. Bankruptcy, export restrictions, regulatory delays and stock allocation decisions can all end up determining whether a child stays seizure-free or returns to a life of repeated admissions. For children with drug-resistant epilepsy, continuity is not a luxury; it is part of the treatment itself.
The Department of Health and Social Care has said access will remain in the short term for NHS and private UK patients, with sufficient stock for the coming months, and that it is working with the UK supplier and Dutch government to understand whether more stock can be made available. That reassurance offers breathing space, but not certainty. Families are still left with a finite window and no clear long-term guarantee.
Seizure control depends on continuity, not just efficacy
This case sits at the intersection of neurology, pharmacy supply and public policy. The clinical issue is not whether Bedrolite works for every patient with epilepsy. The issue is narrower and more urgent: for the children and adults who have already responded, what happens when the only formulation that has kept them stable becomes unavailable? In epilepsy care, that question is not abstract. Breakthrough seizures can strip away independence, education, employment and safety in a matter of days.
For Alfie and Louis, the medicine has done more than reduce seizures. It has restored ordinary life. One boy plays football and has been seizure-free for years; one young man has earned a first-class degree and is living with the kind of stability his family once feared he would never have. The current supply crisis threatens to reverse that progress without any change in the underlying disease.
What remains unresolved is whether the current inventory will bridge patients far enough into the future to prevent treatment interruption, and whether a domestic or alternative supply can be established before the stock problem turns into a seizure emergency.